Africa: New Injectable HIV Treatment Shows Promise in Africa, Study Finds
Nairobi — A new study conducted across three African countries has found that an injectable HIV treatment–Cabotegravir/Rilpivirine (CAB LA + RPV LA), administered every two months–is safe, well tolerated, and preferred by most patients. The Month-12 results, drawn from study sites in Kenya, Uganda, and South Africa, offer renewed hope for improved treatment adherence, fewer…